Chi Sheng Pharma & Biotech Co., Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 01:49 am IST
Share
Chi Sheng Pharma & Biotech Co., Ltd reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 281.99 million compared to TWD 254.91 million a year ago. Revenue was TWD 281.99 million compared to TWD 254.91 million a year ago. Net income was TWD 26.41 million compared to TWD 11.78 million a year ago. Basic earnings per share from continuing operations was TWD 0.46 compared to TWD 0.21 a year ago. Diluted earnings per share from continuing operations was TWD 0.46 compared to TWD 0.21 a year ago.
For the six months, sales was TWD 564.12 million compared to TWD 494.39 million a year ago. Revenue was TWD 564.12 million compared to TWD 494.39 million a year ago. Net income was TWD 52.53 million compared to TWD 24.51 million a year ago. Basic earnings per share from continuing operations was TWD 0.92 compared to TWD 0.43 a year ago. Diluted earnings per share from continuing operations was TWD 0.92 compared to TWD 0.43 a year ago.
Chi Sheng Pharma & Biotech Co., Ltd, formerly Chi Sheng Chemical Corporation is principally engaged in the manufacture and distribution of general medicines and medicinal injections. The Company provides injections, including hemodialysis concentrate, amino acid injection with electrolytes, vitamins, cephalosporin antibiotics, antihistamines and antipruritics, as well as ginkgo injections; oral preparations, including antibiotics, cold syrups and liquid antacid; external medicines, including contact lens fluid, normal saline for wash and povidone-iodine solution, and consumer goods, including functional health foods, skin care products and cosmetics. It also provides medical devices and equipment. The Company distributes its products in domestic markets and to overseas markets, including Mainland China and Southeast Asia.
CHI SHENG PHARMA & BIOTECH CO., LTD 
